<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40567237</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4563</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Hypertension (Dallas, Tex. : 1979)</Title><ISOAbbreviation>Hypertension</ISOAbbreviation></Journal><ArticleTitle>Benefit and Harm of Intensive Blood Pressure Control by Cardiovascular Risk.</ArticleTitle><Pagination><StartPage>1392</StartPage><EndPage>1400</EndPage><MedlinePgn>1392-1400</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/HYPERTENSIONAHA.125.25162</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Current guidelines for blood pressure treatment are stratified by cardiovascular disease (CVD) risk levels. However, the impact of CVD risk on the benefits and harms of intensive blood pressure control remains unknown. This study aims to evaluate the cardiovascular benefits and treatment-related adverse events associated with intensive blood pressure control across different CVD risk levels.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">From the STEP trial (Strategy of Blood Pressure Intervention in Older Hypertensive Patients), 8262 patients were stratified by tertiles of baseline 10-year CVD risk. Benefit and harm were determined as a reduction of primary outcomes and an increase of adverse events, respectively. Cox proportional hazard models were used to examine the association between CVD risk and outcome events in each tertile. The Poisson regression model was used to predict the benefits and harms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">During a median follow-up of 3.32 years, 333 primary outcomes and 611 adverse events occurred. Within each risk tertile, there were lower rates of the primary outcome in the intensive treatment group (overall hazard ratio, 0.76 [95% CI, 0.61-0.94]), and the hazard ratio for adverse events was 1.1 (95% CI, 0.94-1.28). Patients with higher CVD risk had higher absolute risk reduction of the primary outcome and absolute risk increase of adverse events. The predicted benefit-to-harm ratio differed significantly across each CVD risk tertile but favored intensive control overall.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Higher CVD risk was associated with increased benefit and harm from intensive blood pressure control. Although benefit and harm profiles varied across CVD risk levels, the overall benefit was greater than harm in all risk tertiles.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Dong</LastName><ForeName>Xilan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease of China, National Center for Cardiovascular Diseases of China, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (X.D., Q.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ling</LastName><ForeName>Qianhui</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0003-4812-3934</Identifier><AffiliationInfo><Affiliation>Anzhen Hospital, Capital Medical University, Beijing, China (Q.L., J.C.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xueyan</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-8024-7024</Identifier><AffiliationInfo><Affiliation>National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (X.Z.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Qirui</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0009-0007-9340-4520</Identifier><AffiliationInfo><Affiliation>Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease of China, National Center for Cardiovascular Diseases of China, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (X.D., Q.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8928-9570</Identifier><AffiliationInfo><Affiliation>Anzhen Hospital, Capital Medical University, Beijing, China (Q.L., J.C.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hypertension</MedlineTA><NlmUniqueID>7906255</NlmUniqueID><ISSNLinking>0194-911X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="Y">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="Y">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082742" MajorTopicYN="N">Heart Disease Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001795" MajorTopicYN="N">Blood Pressure Determination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">blood pressure</Keyword><Keyword MajorTopicYN="N">cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">follow-up studies</Keyword><Keyword MajorTopicYN="N">heart disease risk factors</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>16</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>26</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40567237</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.125.25162</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>